You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
Part (x) All cannabis outpatient clients by country and usual route of administration (%)
| Country | Inject | Smoke/inhale | Eat/drink | Sniff | Others | Route known (n) | Route unknown | |
|---|---|---|---|---|---|---|---|---|
| Belgium | 0.1 | 98.8 | 0.7 | 0.3 | 0.1 | 1361 | 34 | |
| Bulgaria | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 23 | 0 | |
| Czech Republic | 0.0 | 99.8 | 0.0 | 0.2 | 0.0 | 439 | 0 | |
| Denmark | 0.0 | 98.6 | 1.4 | 0.0 | 0.0 | 2097 | 229 | |
| Germany | 0.2 | 98.0 | 1.2 | 0.3 | 0.3 | 31670 | : | |
| Estonia | : | 100.0 | : | : | : | 28 | : | |
| Ireland | 1 | 0.0 | 99.1 | 0.9 | 0.0 | 0.0 | 1162 | 2 |
| Greece | 0.0 | 99.8 | 0.2 | 0.0 | 0.0 | 633 | 5 | |
| Spain | 1 | 0.0 | 96.5 | 2.4 | 0.6 | 0.4 | 10830 | 380 |
| France | : | 99.3 | 0.6 | : | 0.0 | 15109 | 1665 | |
| Italy | 2 | 0.0 | 95.9 | 1.0 | 2.8 | 0.3 | 7280 | 677 |
| Cyprus | 0.0 | 99.8 | 0.2 | 0.0 | 0.0 | 435 | 1 | |
| Latvia | 3 | 0.4 | 97.8 | 1.3 | 0.4 | 0.0 | 223 | 9 |
| Lithuania | : | : | : | : | : | : | : | |
| Luxembourg | : | 50.0 | : | : | 50.0 | 4 | : | |
| Hungary | 0.2 | 94.2 | 4.6 | 0.8 | 0.1 | 2733 | 21 | |
| Malta | 0.8 | 97.5 | 1.6 | : | : | 122 | : | |
| Netherlands | 0.0 | 99.5 | 0.3 | 0.2 | 0.0 | 3906 | 1727 | |
| Austria | 0.0 | 97.8 | 1.6 | 0.5 | 0.1 | 757 | 20 | |
| Poland | 4 | : | 97.6 | 0.8 | 1.6 | : | 125 | 1 |
| Portugal | 5 | 0.0 | 98.6 | 1.4 | 0.0 | 0.0 | 352 | 173 |
| Romania | 0.0 | 97.0 | 3.0 | 0.0 | 0.0 | 66 | 0 | |
| Slovenia | : | 100.0 | : | : | : | 44 | : | |
| Slovakia | 1.3 | 92.9 | 1.9 | 3.8 | 0.0 | 156 | 1 | |
| Finland | 0.7 | 98.6 | 0.7 | 0.0 | 0.0 | 138 | 4 | |
| Sweden | 1 | 0.0 | 95.9 | 3.8 | 0.3 | 0.0 | 1025 | 16 |
| United Kingdom | 6 | 0.0 | 96.0 | 2.8 | 0.6 | 0.5 | 22444 | 716 |
| Croatia | 0.0 | 100.0 | 0.0 | 0.0 | : | 897 | 0 | |
| Turkey | : | : | : | : | : | : | : | |
| Norway | 7 | 0.0 | 97.2 | 2.8 | 0.0 | 0.0 | 36 | 4 |
| Total | 0.1 | 97.5 | 1.6 | 0.5 | 0.3 | 104095 | 5685 |
Notes:
: Indicates no data are available.
Percentages are of clients whose route of administration is known (n)
1 - Data are from 2010.
2 - In 2010 around 27% of all clients and 32% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.
3 - In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.
4 - Data are from 2010. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.
5 - In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria. Caution should be made when comparing 2010 data with previous years.
6 - Data are from 1st of April 2010 to 31st March 2011.
7 - In Norway the criteria for selecting and grouping cases are main ICD-10 diagnosis codes F11-F16 and F18-F19.
For more information relative to the treatment centre type, please see Table TDI-7.
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Source:
Reitox national reports 2012 — TDI — outpatient treatment centres.